全磁悬浮离心流循环泵低强度抗凝评估——MAGENTUM 1 研究
MAGENTUM 1 为前瞻性单臂先导研究,15 例植入 HeartMate 3 左心室辅助系统的晚期心衰患者,在标准华法林抗凝(INR 2.0–3.0)加阿司匹林 6 周后转为低强度抗凝(INR 1.5–1.9)。主要复合终点(无泵血栓、致残性卒中或大出血生存)在 14/15 例(93±6%)达到,未发生血栓事件;作者认为低强度抗凝在短期 6 个月内可行且安全,需大规模试验验证。
要点
- 植入后 6 周标准华法林抗凝(INR 2.0–3.0)加阿司匹林,随后转为 INR 1.5–1.9 低强度抗凝。
- 主要复合终点在 14/15 例(93±6%)达到,1 例发生复发性胃肠道出血。
- 低抗凝阶段(6 周至 6 个月)治疗窗内时间(TTR)为 75.3±8.6%,未发生血栓事件。
核心结论
- 该先导研究提示,以 INR 1.5–1.9 为目标的低强度抗凝在 HeartMate 3 心脏泵植入后 6 个月短期阶段可行且安全,目前需要大规模试验。
研究设计与样本
- MAGENTUM 1 为前瞻性单臂先导研究,评估 HeartMate 3 泵植入患者低强度华法林抗凝的安全性。
- 共纳入 15 例晚期心衰患者(平均年龄 57.3±13.3 岁),其中 13 例男性,67% 为 INTERMACS 2 或 3 级,不限桥接移植或目的地治疗目标。
- 植入后标准华法林抗凝(INR 2.0–3.0)加阿司匹林 6 周,随后转为 INR 1.5–1.9 低强度抗凝。
- 主要终点为无泵血栓、致残性卒中(改良 Rankin 评分 >3)或大出血(除外围术期出血)的复合生存,随访至少 6 个月。
- 采用 Rosendaal 法测量治疗窗内时间(TTR)评估抗凝达标效果,并制定实施监测泵血栓征象的安全算法。
主要发现
- 主要复合终点在 14/15 例(93±6%)患者中达到,1 例发生复发性胃肠道出血。
- 低抗凝阶段(6 周至 6 个月)的 TTR 为 75.3±8.6%。
- 未发生血栓事件。
临床怎么用
- 作者认为,以 INR 1.5–1.9 为目标的低强度抗凝在 HeartMate 3 植入后 6 个月短期阶段可行且安全。
- 作者指出目前需要大规模试验。
局限性
- 原文结论指出目前需要大规模试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The HeartMate 3 left ventricular assist system is engineered to avoid pump thrombosis, yet bleeding complications persist. We investigated the safety of low-intensity anti-coagulation in patients with the HeartMate 3. METHODS: The Minimal AnticoaGulation EvaluatioNTo aUgment heMocompatibility (MAGENTUM 1) pilot study is a prospective, single-arm study of low-intensity warfarin anti-coagulation in patients implanted with the HeartMate 3 pump. After standard warfarin anti-coagulation (international normalized ratio [INR] 2.0 to 3.0) and aspirin for 6 weeks post-implant, patients were transitioned to a lower INR target range of 1.5 to 1.9. The primary end-point was a composite of survival free of pump thrombosis, disabling stroke (modified Rankin score [MRS] >3), or major bleeding (excluding peri-operative bleeding) with at least 6-month post-implant follow-up. Time in therapeutic range (TTR) was measured to assess anti-coagulation target efficacy using the Rosendaal method. A safety algorithm to monitor for signs of pump thrombosis was developed and implemented. RESULTS: We enrolled 15 patients (mean age 57.3 ± 13.3 years), 13 men with advanced heart failure (67% with INTERMACS Profiles 2 or 3), irrespective of therapeutic goal of bridge-to-transplant or destination therapy. The primary end-point was met in 14 of 15 (93 ± 6%) patients; 1 patient developed recurrent gastrointestinal bleeding. The TTR during the reduced anti-coagulation phase (6 weeks to 6 months) was 75.3 ± 8.6%. No thrombotic events occurred. CONCLUSIONS: This pilot study suggests low-intensity anti-coagulation targeting an INR between 1.5 and 1.9 is achievable and safe with the HeartMate 3 cardiac pump in the short-term phase, 6-months post-implant. A large-scale trial is now warranted.
引用
- Netuka I, Ivák P, Tučanová Z, et al. Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump-the MAGENTUM 1 study. J Heart Lung Transplant. 2018. PMID: 29655662. doi:10.1016/j.healun.2018.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。